BioCentury
ARTICLE | Emerging Company Profile

Phenomic AI: phenotypic screening for antibody discovery

How Phenomic AI’s platform could speed up antibody screening

April 18, 2019 11:51 AM UTC

Phenomic is developing a deep-learning platform that uses high-content imaging and neural networks to analyze phenotypic changes in disease models to discover therapeutic antibodies more rapidly than conventional methods.

Current image analysis tools work well for simple cell-based screens, said Phenomic AI CEO Sam Cooper. Although industry has lacked tools for analyzing images from co-cultures, organoids and other complex phenotypic models that incorporate multiple cell types and signaling networks involved in disease, advances in computational tools have renewed interest in these phenotypic screening models (see “The Phenomics Phenomenon”)...